- Home
- SOPH vs NMRA Comparison
SOPH vs NMRA Comparison
Compare SOPH & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOPH
- NMRA
- Stock Information
- Founded
- SOPH 2011
- NMRA 2019
- Country
- SOPH Switzerland
- NMRA United States
- Employees
- SOPH N/A
- NMRA N/A
- Industry
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- NMRA
- Sector
- SOPH Health Care
- NMRA
- Exchange
- SOPH Nasdaq
- NMRA Nasdaq
- Market Cap
- SOPH 231.8M
- NMRA 268.5M
- IPO Year
- SOPH 2021
- NMRA 2023
- Fundamental
- Price
- SOPH $4.63
- NMRA $1.94
- Analyst Decision
- SOPH
- NMRA Hold
- Analyst Count
- SOPH 0
- NMRA 8
- Target Price
- SOPH N/A
- NMRA $5.83
- AVG Volume (30 Days)
- SOPH 98.2K
- NMRA 506.9K
- Earning Date
- SOPH 11-04-2025
- NMRA 11-11-2025
- Dividend Yield
- SOPH N/A
- NMRA N/A
- EPS Growth
- SOPH N/A
- NMRA N/A
- EPS
- SOPH N/A
- NMRA N/A
- Revenue
- SOPH $69,688,000.00
- NMRA N/A
- Revenue This Year
- SOPH $16.60
- NMRA N/A
- Revenue Next Year
- SOPH $18.77
- NMRA N/A
- P/E Ratio
- SOPH N/A
- NMRA N/A
- Revenue Growth
- SOPH 7.32
- NMRA N/A
- 52 Week Low
- SOPH $2.58
- NMRA $0.61
- 52 Week High
- SOPH $4.92
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- SOPH N/A
- NMRA 58.78
- Support Level
- SOPH N/A
- NMRA $1.70
- Resistance Level
- SOPH N/A
- NMRA $1.93
- Average True Range (ATR)
- SOPH 0.00
- NMRA 0.13
- MACD
- SOPH 0.00
- NMRA 0.01
- Stochastic Oscillator
- SOPH 0.00
- NMRA 82.05
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.